Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

by divibasicbldev | Jun 16, 2026 | Press Releases

— Remains on track to release interim NF1 data update in Q4 2026 —- Additional dose levels and longer treatment period added — MIAMI, June 16, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the...

Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference

by divibasicbldev | Jun 15, 2026 | Press Releases

— Company will engage with NF1 community following recent FDA Fast Track and Rare Pediatric Disease Designations for lead NF1 treatment candidate PAS-004 – – Participants interested in meeting with Pasithea are encouraged to contact in advance to...

Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

by divibasicbldev | Jun 2, 2026 | Press Releases

Orphan Drug Designation is intended to support the development of therapies for rare diseases affecting fewer than 200,000 people in the United StatesMIAMI, June 02, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or...

Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer

by divibasicbldev | May 4, 2026 | Press Releases

MIAMI, May 04, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the...

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

by divibasicbldev | Apr 20, 2026 | Press Releases

Rare Pediatric Disease Designation may render Pasithea eligible to receive a Priority Review Voucher (PRV)MIAMI, April 20, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage...